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Abstract 
Encapsulated fish oil products continue to be of high interest, particularly 
concerning labelling claims and oxidative status. Thus, the present study analysed 
twenty-three encapsulated fish oil products from the UK for their lipid and fatty acid 
composition as well as oxidation parameters. Oil contents ranged from 91.4-118.9% of 
the manufacturers stated level. Lipid class analyses revealed three different types of oil 
products consisting of either triacylglycerol (TAG), ethyl ester (EE) or in combination 
(EE/TAG). Fatty acid profiles varied according to oil form with long-chain omega-3 
fatty acids, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), more 
concentrated in EE compared to TAG-based oils with TAG/EE oils containing 
intermediary levels. Twelve products had EPA+DHA contents lower than advertised, 
although this was reduced to 11 when the actual measured capsule oil content was taken 
into consideration. All products had peroxide (PV) and anisidine values below those 
set by pharmacopeias, although four products had a PV above the industry set limit of 
5 meq.kg-1. No relationships were found between oxidative parameters and missing 
EPA+DHA contents, although a significant relationship was observed between PV and 
days to expiry. In summary, encapsulated fish oil products on the UK market are not 
oxidized and meet regulatory guidelines with respect to EPA+DHA contents and 
oxidative status.  
 
Practical applications 
The study highlights the importance of quantifying the actual capsule oil content when 
determining EPA+DHA levels with respect to label claims. Furthermore, it also places 
results into context regarding regulatory guidelines demonstrating to regulatory bodies 
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and consumers alike that UK fish oil products do meet specification and are not 
oxidised.  
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1. Introduction 
The omega-3 (n-3) long-chain polyunsaturated fatty acids (LC-PUFA), 
eicosapentaenoic acid (EPA; 20:5n-3), docosahexaenoic acid (DHA; 22:6n-3) and, to 
some extent, docosapentaenoic acid (DPA; 22:5n-3), are widely regarded as being 
beneficial to human health and development, being key to neural function as well as in 
reducing the incidence of chronic pathologies including cardiovascular and 
inflammatory diseases and cancer among others [1,2]. However, humans are inefficient 
at endogenously producing sufficient quantities of n-3 LC-PUFA and therefore require 
these beneficial fatty acids in the diet [1]. The main dietary sources of these fatty acids 
are from fish and seafood, but especially oily fish such as mackerel, sardines and 
salmon [3,4]. Consequently, global health authorities advocate consuming two portions 
of fish per week, of which one should be oily, as part of a healthy diet in order to obtain 
a daily dose of 250-1000 mg EPA+DHA [5]. Nevertheless, the majority of the western 
world fails to adhere to these guidelines, resulting in low EPA+DHA blood levels that 
are considered likely to increase the risk of chronic disease [6].  
Nutritional supplements are an effective approach for consumers wanting to 
increase their dietary nutrient intake, and account for 13% of the global market share 
for EPA/DHA packaged products, excluding fish, behind infant formula and fortified 
foods [7]. Of these, encapsulated fish oil products are the most popular form of 
supplement and are widely available throughout developed countries in either natural 
or concentrated forms. Despite the majority of commercially available fish oil products 
meeting or exceeding manufacturers’ specifications, many studies have reported the 
EPA and/or DHA content of some products analysed to be lower than that stated on 
the label, although there is some disagreement as to what is deemed as being reasonably 
accurate to the label claim [8-24]. Opinions vary as to the exact cause for the missing 
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EPA and/or DHA contents with autoxidation considered to be the most likely factor. 
However, the integrity of the analytical techniques employed and the results obtained 
in some of these studies, most notably Albert et al. [9], has also been disputed with 
recommendations that laboratories use standardised and/or accredited methods 
pertinent to the matrix being tested, together with the validation of methods through 
regular participation in inter-laboratory proficiency tests [16,21,25].  
Marine oils are particularly susceptible to oxidative damage, more than other oils, 
due to their high number of double bonds, and position within the fatty acid chain, as 
a consequence of their favourable PUFA content [26]. Lipid oxidation results in the 
formation of free radicals and lipid hydroperoxides that may undergo further reaction 
into secondary oxidation products such as aldehydes, ketones and alcohols. 
Consequently, the oxidative status of oils can be evaluated through several methods 
such as measuring the peroxide value (PV) and para-anisidine value (p-AV), among 
others, as primary and secondary oxidative products, respectively. Industry regulators, 
including the British and European Pharmacopeias, have limits for n-3 LC-PUFA-
containing oils at 10 meq.kg-1 for PV, 30 for p-AV and 50 for the total oxidation value 
(TOTOX), a combination of both PV and p-AV to give an assessment of total oxidation 
[27,28]. The Global Organization for EPA and DHA omega-3s (GOED), on the other 
hand, an industry association body commonly representing fish oil manufacturers, have 
set their own more stringent limits for n-3 LC-PUFA oils, through a Voluntary 
Monograph of 5 meq.kg-1, 20 and 26 for PV, p-AV and TOTOX, respectively, as a 
means of maintaining products of high quality [28,29]. 
Encapsulating marine oils is one method of improving the oxidative stability of n-3 
LC-PUFA marine oils [26]. Nevertheless, some studies have reported that the oxidative 
stability of some encapsulated marine oil products may be of concern with regards to 
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quality and/or safety [9-15,30-32]. In particular, there has been some controversy over 
the high levels of oxidation found in n-3 LC-PUFA oils from Australia and New 
Zealand reported by Albert et al. [9] with suggestions that assay interferences due to 
the types of oils tested together with the methodologies used may have resulted in false 
positive results [16,21,28]. Nevertheless, the monitoring of fish oil products on the 
market is of importance in ensuring that products are of a high quality and contain the 
specified contents to the final consumer. 
Thus, the present study looked at the lipid and fatty acid composition, particularly 
with respect to EPA and DHA in relation to labelled content, as well as the oxidative 
status, of encapsulated fish oil products available in the UK and discussed how they 
compare to regulatory guidelines. 
 
2. Materials and Methods 
2.1. Sample collection and preparation 
Twenty-three encapsulated n-3 LC-PUFA products, consisting of branded and own-
brand standard fish oil and/or fish oil concentrates, were purchased from a variety of 
retailers and health outlets during January 2017 (see Table 1 for details). Sample bottles 
remained unopened until the day of analysis and were stored in a cool, dry place in 
accordance with the manufacturer’s recommendations. Prior to the different analytical 
techniques, several capsules from each product, enough to provide a sufficient quantity 
of oil for the required methodology (minimum 5 capsules per product), were 
individually weighed, pierced to remove the oil content before rinsing with isohexane, 
and leaving overnight in vacuo in a desiccator. Empty capsules were reweighed and 
the capsule oil content calculated. Oil removed from capsules was stored under oxygen-
free nitrogen and used the same day to minimize oxidation. For lipid class and fatty 
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acid analyses, a total lipid solution of 10mg.ml-1 was prepared by weighing a known 
quantity of oil and making up to concentration with chloroform/methanol (2:1, v/v). 
All analyses were carried out in February 2017 and performed blind and in duplicate, 
with a relative standard deviation between replicates <10% deemed acceptable, and the 
mean value reported. 
 
2.2. Reagents and chemicals 
All solvents used in the analytical techniques reported were of HPLC grade, with 
glacial acetic acid and potassium iodide of analytical reagent grade (Fisher Scientific, 
Loughborough, UK). Concentrated sulphuric acid (Aristar®, sp. gr. 1.84), analytical 
reagent grade starch (potato), potassium hydrogen carbonate (AnalaR Normapur®) and 
sodium hydroxide pellets (AnalaR Normapur®) were purchased from VWR 
International Ltd. (Poole, UK). Both 2-thiobarbituric acid (≥98%) and p-anisidine 
(≥98%) were obtained from Sigma-Aldrich (Poole, UK) together with trichloroacetic 
acid and phenolphthalein indicator solution, which were American Chemical Society 
(ACS) grade reagents. Sodium thiosulphate solution (Titrisol®) was purchased from 
Merck (Darmstadt, Germany). Nanopure water was collected from a Milli-Q ultrapure 
purification system (0.22 µm; Millipore, UK). Compressed nitrogen (oxygen free, 
≥99.99% nitrogen,  300bar EVOS™ Ci 50 L cylinder) was obtained from BOC Ltd 
(Glasgow, UK). 
 
2.3. Lipid class and fatty acid composition 
Lipid classes were separated by single development high-performance thin-layer 
chromatography (HPTLC) using isohexane/diethyl ether/acetic acid (90:10:1, by vol.) 
as the development system [33]. Classes were visualised by charring at 160oC for 15 
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min after spraying with 3% (w/v) aqueous cupric acetate containing 8% (v/v) 
phosphoric acid and quantified by densitometry using a CAMAG-3 TLC scanner 
(Version Firmware 1.14.16; CAMAG, Muttenz, Switzerland) with winCATS Planar 
Chromatography Manager. Identities of individual classes were confirmed by 
comparison with reference to Rf values of authentic standards run alongside samples. 
Fatty acid methyl esters (FAME) from total lipid (1 mg) were prepared by acid-
catalysed transmethylation, using 2 ml of 1% (v/v) solution of sulphuric acid in 
methanol and 1 ml toluene, at 50oC for 16h [34]. The reaction was stopped with 2% 
(w/v) potassium bicarbonate in nanopure water before FAME were extracted and 
purified as described previously [35]. FAME were separated and quantified by gas 
liquid chromatography (GC) using a Fisons GC-8160 (Thermo Scientific, Milan, Italy) 
equipped with a 30 m x 0.32 mm i.d. x 0.25 µm ZB-wax column (Phenomenex, 
Cheshire, UK), ‘on column’ injection and flame ionization detection. Hydrogen was 
used as carrier gas with the initial oven thermal gradient from 50oC to 150oC at 
40oC.min-1 to a final temperature of 230oC at 2oC.min-1. Individual FAME were 
identified by comparison to known standards (Restek 20-FAME Marine Oil Standard; 
Thames Restek UK Ltd., Buckinghamshire, UK) and published data [35]. The data 
were collected and processed using Chromcard for Windows (Version 1.19; 
Thermoquest Italia S.p.A., Milan, Italy). Heptadecanoic acid (17:0) was used as 
internal standard to calculate fatty acids on an absolute basis (mg.capsule-1).   
 
2.4. Oxidative parameters 
Peroxide value (PV) was based upon the Association of Official Analytical 
Chemists (AOAC) Method 965.33 [36]. Approximately, 1 ml of oil was weighed into 
a conical flask and dissolved in 20 ml glacial acetic acid/chloroform (2:1, v/v) before 
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7 drops of saturated potassium iodide (KI) were added, swirled to mix and left in the 
dark. After 10 min, 15 ml of 10% KI solution together with 1 ml of starch solution was 
added. The resulting solution was titrated with 0.002 M sodium thiosulphate (Na2S2O3) 
with the endpoint reached when the chalky white residue had dissipated and the 
solution reverted back to its original colour prior to the addition of starch. PV was 
calculated as: PV (meq.kg-1 oil) = [(Vs-Vb) × M/W] × 1000, where W is oil mass (g), 
Vs the volume (ml) of 0.002 M Na2S2O3 solution titrated, Vb the volume of Na2S2O3 
titrated for the blank sample and M the molarity of the Na2S2O3 solution. 
Anisidine value (p-AV) was determined by absorbance spectrophotometry after 
reaction with para-anisidine in accordance with the International Union of Pure and 
Applied Chemistry (IUPAC) Method 2.201 [37]. Briefly, 0.3 g of oil sample was 
weighed in a 25 ml volumetric flask and made up to volume with isohexane and mixed. 
The absorbance (A1) was measured at 350 nm against a reference blank of 5 ml 
isohexane containing 1 ml glacial acetic acid. A reagent solution comprising 1 ml 
0.25% para-anisidine in glacial acetic acid was added to the sample and left for 10 min 
in the dark to react. The absorbance (A2) was measured against 5 ml isohexane 
containing 1 ml 0.25% para-anisidine in glacial acetic acid and p-AV calculated as: p-
AV = 25 × [1.2 × (A2-A1)/W], where W is the oil mass (g).   
The total oxidation (TOTOX) value was derived using the results from the PV and 
p-AV analysis, calculated as TOTOX = 2 x PV + p-AV. 
Thiobarbituric acid reactive substances (TBARS) analysis was based on the method 
of Sørensen and Jørgensen [38], which measures malondialdehyde (MDA) formed 
during lipid oxidation as a result of the degradation of PUFA [39]. Approximately, 1 g 
of oil was weighed into 50 ml centrifuge tubes before the addition of 25 ml 7.5% 
trichloroacetic acid (TCA) solution, vortex mixed and centrifuged for 5 min at 3399 g. 
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The TCA solution containing the extract was transferred into a 7 ml glass vial and 2 ml 
of 0.02 M 2-thiobarbituric acid (TBA) reagent added and mixed. Samples were left to 
stand in a water bath set at 100oC for 35 min, cooled and vortex mixed before degassing 
in a sonicator bath. The samples were centrifuged for 5 min at 3399 g before being 
transferred to cuvettes and the absorbance measured at 532 nm. A blank sample 
containing 2 ml of distilled water with 2 ml TBA reagent as well as a standard 
containing 2 ml of 1,1,3,3-tetraethoxypropane (TEP) solution with 2 ml of TBA reagent 
was also measured. TBARS was calculated as: TBARS (mg MDA.kg-1) = [ABssmp × 
Wstd × VTCA × MMDA × 1000]/[Absstd ×Wsmp × F × MTEP], where Abssmp and Absstd are 
the absorbances of the sample and the standard at 532 nm, respectively, Wstd the 
standard weight (mg), VTCA the volume of TCA added to the sample (ml), MMDA the 
molecular weight of MDA (72.06 g.mol-1), Wsmp the sample weight (g), F the dilution 
factor for the TEP standard (16667) and MTEP the molecular weight of TEP (220.3 
g.mol-1).   
The free fatty acid (FFA) content of oils was determined according to the American 
Oil Chemists Society (AOCS) Official Method Ca 5a-40 [40]. Approximately 1 g of 
oil was weighed into a 250 ml conical flask and dissolved with 75 ml of 95% ethyl 
alcohol at 50oC before the addition of 2 ml phenolphthalein indicator solution. The 
sample was titrated with 0.25 M NaOH until the appearance of a permanent pink colour 
which persisted for 30 sec. FFA was calculated as: FFA (% as oleic acid) = [V × 0.25 
× 28.2]/w, where V is the volume of NaOH titrated (ml) and w is the sample weight 
(g).  
 
2.5. Quality assurance 
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The method of performance of the analytical procedures described above were 
further validated through the satisfactory annual performance of interlaboratory 
proficiency test including: the European Federation for the Science and Technology of 
Lipids, organised by the German Society for Fat Science (DGF, Frankfurt, Germany), 
for fatty acid content and oxidative parameters; Masterlab Analytical Services BV 
(Boxmeer, Netherlands) for analytical methods routinely used in the feed, oil, fish 
producing and technology sectors; and the American Oil Chemist’s Society (AOCS, 
Illinois, USA) for the fatty acid content of marine oils. 
 
2.6. Statistical tests 
Relationships between variables (e.g. oxidative parameters and days to expiry) were 
assessed using Pearson’s correlation coefficient (r). Runs test was used to check 
linearity with failed data indicating a non-linear relationship (GraphPad Instat® v 
3.01). A significance of P<0.05 was applied to all tests. 
 
3. Results and discussion 
3.1. Oil capsule content 
Overall, the oil capsule content of the 23 analysed sample products was found to be 
relatively consistent with that declared on the product label (Table 1). Only sample 7 
contained noticeably less than the manufactures stated level (91.4% of the labelled 
capsule oil content), whereas samples 11 and 13 were found to be in excess of the 
advertised capsule oil content (117.1 and 118.9%, respectively) (Figure 1). This finding 
is similar to that of Albert et al. [9] and Kolanowski [11] who reported an oil capsule 
content range of 95.6-114.2% and 97.2-101.8% respectively, relative to the product 
label. Nevertheless, although the oil capsule contents in the present study were >90% 
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of the manufacturers claimed content such discrepancies will invariably affect the 
overall fatty acid content (mg.capsule-1) delivered to the consumer.  
 
3.2. Lipid class and fatty acid composition  
Lipid class compositions of oil from capsules analysed in the present study revealed 
three different types of oil products, consisting mainly of triacylglycerol (TAG), ethyl 
ester (EE) or a combination of both (Table 2). This reflects the wide range of n-3 
supplements available on the market in either natural TAG or concentrated forms of 
fatty acids, particularly with respect to n-3 LC-PUFA content. The standard fish oil 
products (samples 1-16) were generally comprised of TAG as the main lipid 
component (81.0-92.0%) and were largely characterized by high levels of myristic 
(14:0; range 3.6-7.2%), palmitic (16:0; range 9.8-18.8%) and oleic (18:1n-9; range 7.1-
17.8%) acids, with EPA+DHA ranging from 19.8-32.0% of total fatty acids (Table 3). 
In contrast, samples 21-23 were fish oil concentrates with highly elevated levels of n-
3 LC-PUFA (47.5-85.6%) with EPA+DHA levels of 38.0-75.2% of total fatty acids 
and EE as the predominant lipid class (94.6-98.0%). The EEs are chemically produced 
by trans-esterification of TAG fish oils with ethanol, which allows for the subsequent 
selective concentration of n-3 LC-PUFA, especially EPA and DHA, to levels greater 
than that found in natural fish oils [41]. However, the bioavailability and uptake of n-
3 LC-PUFA as EEs compared to TAG is widely contested, with greater bioavailability 
suggested for TAG [42]. Although product packaging may specify that supplements 
are fish oil concentrates, therefore containing higher amounts of EPA and DHA, the 
oil form is rarely listed. Concentrated EE forms of EPA and DHA may be re-esterified 
back to TAG, although the conversion process inevitably increases the cost of the final 
product and, as such, many concentrates are left in the form of EE as observed in the 
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present study. Samples 17-20 on the other hand, contained a mix of both fish oil and 
fish oil concentrates and were therefore comprised of both TAG (21-28.8%) and EE 
(54.7-69.2%). Subsequently, these products contained intermediary levels of 
EPA+DHA of 35.7-48.6% of total fatty acids. Nonetheless all profiles reported are 
comparable to encapsulated fish oil products sampled from Europe [11], America 
[18,20,23], Brazil [10] and Australasia [17,19,21,43]. The origin of the oils can be 
further differentiated by their fatty acid profiles using marker fatty acids (Table 3). For 
example, northern hemisphere fish oils tend to exhibit higher levels of gondoic; (20:1n-
9) and cetoleic (22:1n-11) acids, associated with the consumption of calanoid copepods 
by high-latitude zooplanktonivorous fish [44], as well as lower total monoene levels, 
and EPA:DHA ratios of around 1.0 [4]. Thus, profiles of samples 1-5, 7-9 and 17-19 
all suggest that these products contained northern hemisphere fish oils. Indeed, these 
samples had cod liver oil as either a component or sole oil source (Table 1). However, 
sample 6 also had cod liver oil listed as an ingredient although the profile would suggest 
that this is not the case, as evinced by lower levels of both 20:1n-9 (1.9%) and 22:1n-
11 (1.6%) compared to other cod liver oil capsule products (range 5.4-12.0 and 3.7-
8.9, 20:1n-9 and 22:1n-11, respectively). It is possible that these marker fatty acids may 
have been diluted by the inclusion of other fish oils which may have been of southern 
hemisphere origin. Most encapsulated fish oil products available on the market are 
blends of fish oils and their derivatives. For example, samples 3-5, 7-9 and 17-19 all 
contained a combination of cod liver oil and other fish oils and exhibited similar 
patterns of the marker fatty acids, albeit diluted, compared to samples 1 and 2 which 
contained only cod liver oil. Additionally, sample 11 contained a higher level of the 
plant-derived omega-6 fatty acids, linoleic (18:2n-6, 17.0%) and gamma-linolenic 
acids (18:3n-6, 2.4%). This can be attributed to the inclusion of evening primrose oil, 
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Oenothera biennis, which is characterized by high levels of these fatty acids and has 
been used to treat systemic disease marked by chronic inflammation, although its 
efficacy remains disputed [45,46]. Fish oil capsules, nevertheless, are primarily 
consumed for their health benefits related to their n-3 LC-PUFA content, specifically 
EPA and DHA. 
 
3.3. EPA and DHA content  
Of the 23 capsule products analysed, 12 were found to contain lower EPA+DHA 
levels than the content stipulated on the product packaging when the expected oil 
content value was used (Figure 2). However, this was reduced to 11 products when the 
actual oil capsule content measured was taken into account, with sample 13 increasing 
from 94.2 to 112.0% of the labelled EPA+DHA content due to a higher than expected 
capsule oil content (refer to Table 1). Equally, sample 11 would have yielded just 80% 
of the stated EPA+DHA level had the specified capsule content been used (0.40 g), 
increasing instead to 94.7% of the labelled value when the actual capsule weight was 
applied (0.47 g). This further highlighted the importance of quantifying the capsule oil 
content rather than relying on the declared value when determining the ‘true’ 
EPA+DHA content of encapsulated products. 
Many studies have reported lower than claimed EPA+DHA levels in marine 
products available from Europe [8,11], Australasia [9,16,17,19,21,24], North and 
South America [8,10,15,20,22,23], Korea [12] and Africa [13,14], and the current study 
is no exception. However, there is general disagreement between studies over what 
tolerance level is considered as being reasonably accurate to the label claim. Opperman 
et al. [13] for example, applied a range of 90-100% of the claimed EPA+DHA content 
as being acceptable. This would have resulted in one sample from the present study 
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under-delivering (sample 16, 88.9%), whereas 9 samples over-delivered. In Europe, 
where the current samples tested are marketed, the declared values on product labels 
are generally based on average values from the manufacturer’s analysis in accordance 
with 200/46/EC directive of the European Parliament and Council [47]. Although the 
base ingredients may remain the same, e.g. cod liver or fish body oils, their lipid and 
fatty acid composition is dependent upon a variety of factors including fish species, 
age and nutritional status, as well as environmental factors [48,49]. Manufacturers and 
regulators will therefore allow for some variation between fish oil batches when 
formulating the final product as it is not always possible to contain the exact nutrient 
level labelled. Accordingly, tolerances of nutrient contents exist for food labelling 
purposes to ensure that consumers are not being misled. For example, the European 
Commission’s Guidance document relating to food supplements with regards to setting 
tolerances for nutrient values declared on a label specifies a ± 40% tolerance for 
polyunsaturated fatty acids [50]. However, this document is only advisory, with no 
formal legal status, with the ultimate responsibility for the interpretation of the law 
lying with the European Court of Justice. Interestingly, companies in the UK have for 
many years tended to work to tolerances of ± 20% as part of their own strict measures 
for quality control. Comparably, the US Food and Drug Administration’s (US FDA) 
labelling requirements state that “the nutrient content of the composite must be at least 
equal to 80 percent of the value for that nutrient declared on the label” [51], whereas 
the Therapeutic Goods Administration (TGA) for Australia indicate that a product 
should contain at least 90% of its declared content [52]. Thus, despite some 
encapsulated products falling below the EPA+DHA levels claimed on the label, only 
one out of twenty-three products (4.3% of total products tested) would have failed the 
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TGA standards, although all products met the specifications laid out by US and, more 
importantly, European regulators where all products from the present study are sold. 
 
3.4. Oxidative status of encapsulated oils  
In addition to the lower than claimed EPA+DHA levels, several studies have also 
suggested that the oxidised content of marine oil supplements to be at a level that may 
be of concern with regards to quality [9-15,30-32]. In the present study, all sample 
products were found to have PV, p-AV and TOTOX values below the respective limits 
of 10 meq.kg-1, 30 and 50 respectively, set out by the British and European 
pharmacopeial standards for fish oils [25] (Table 4), although TOTOX is not 
technically recognized by pharmacopeias as it is only considered a convenient measure 
of oxidation [39]. Nevertheless, four out of the twenty-three products analysed (17.3%) 
had a PV greater than the 5 meq.kg-1 limit recommended by the more stringent GOED 
Voluntary Monograph for EPA and DHA oils [28,29]. This is similar to the 28% non-
compliance reported by Bannenberg et al. [16], but far fewer than the 83% found by 
Albert et al [9], who analysed 47 and 36 fish oil products from the Australasian market, 
respectively. Limits used in the GOED Voluntary Monograph have been voluntarily 
set by the fish oil manufacturers themselves, and are generally stricter than 
pharmacopeial standards and regulations to ensure finished fish oil products are of a 
high quality [28,29]. However, the high non-compliance rate reported by Albert et al. 
[9] has been challenged by others with particular criticism directed towards the 
analytical methods and types of fish oil products tested [16,21,25,28]. Similarly, 
follow-up studies found Australasian fish oil products to have a greater compliance, in 
terms of EPA+DHA and oxidation status, than previously reported [16,21,24,28]. 
Many of the samples analysed by Albert et al. [9] for example contained flavourings, 
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often used to mask the ‘fishy’ taste, or whose oils were pigmented. Such parameters 
can interfere with assays, particularly p-AV, as flavoured compounds generally contain 
aldehydes and pigments can directly affect the colormetric measurement that may 
potentially give false positive readings [16,21,28,53]. Consequently, GOED released 
technical guidelines to assist in the selection of appropriate methods for analysing n-3 
oils [53], with others further recommending methods that are both accredited and 
validated through regular participation in inter-laboratory ring-tests for the matrix in 
question [16,21,25]. Thus, despite the availability of pigmented (e.g. virgin salmon oil) 
and flavoured fish oil products in the UK, all fish oils tested in the present study were 
intentionally selected to be free of any flavouring or pigmentation to remove any 
potential conflict with results. 
Of particular interest to note is that products containing EE fish oil concentrates, as 
either the sole lipid source (samples 22 and 23, 6.84 and 7.04 meq.kg-1, respectively) 
or in combination with TAG (samples 19 and 20, 5.20 and 6.76 meq.kg-1), tended to 
be more oxidised, at least in terms of their PV being above the recommended GOED 
level. Oxidation has been found to occur at a faster rate in EE compared to TAG fish 
oils containing similar EPA and DHA contents [54]. Furthermore, these four EE 
products also had the highest levels of DHA (16.8, 19.7, 23.8 and 22.2%, samples 19, 
20, 22 and 23, respectively) as compared to TAG-only (samples 1-16, range 6.5-12.9%) 
and other EE/TAG (15.8 and 16.0%, sample 17 and 18, respectively) and EE oils 
(12.2%, sample 21), which is more prone to autoxidation than EPA [55]. Tentatively, 
this would suggest that there is more readily oxidised substrate available, which may 
subsequently result in a net loss of these fatty acids. In fact, three of these samples with 
PV > 6.0 meq.kg-1, i.e. samples 20, 22 and 23, also had lower contents of EPA+DHA 
than stated on the product label. Several authors have speculated that oxidative damage 
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was most likely the main cause for missing EPA and/or DHA in fish oil products 
[9,18,23], with Albert et al. [9] observing a relationship of missing EPA+DHA contents 
with AV and TOTOX values. However, in the current study both the p-AV and 
TOTOX values were below GOED’s limits of 20 and 26, respectively (Table 4), and 
no significant relationships with missing EPA+DHA contents were found (P>0.05). 
Moreover, the additional secondary oxidation products measured, i.e. TBARS, a 
widely used indicator of MDA formation and lipid peroxidation, together with FFA 
levels also exhibited no obvious sign of oxidation with values ranging between 0.11-
1.39 mg MDA.kg-1 and 0.31-1.19%, for TBARS and FFA, respectively (Table 4). Fish 
oils may undergo clean-up during the manufacturing process, typically by thin-film 
distillation or deodorization coupled with active carbon, to remove undesirables such 
as FFA as well as environmental pollutants without affecting fatty acid profiles [12,56]. 
Moreover, Bannenberg et al. [16] re-examined the oxidative status and EPA and DHA 
contents of fish oil products one year after they had originally been tested and had 
passed their expiry dates and found that, although both PV and p-AV had increased, 
EPA and DHA did not differ significantly from the levels when first tested. Similarly, 
Ritter et al. [54] also found no evidence for a significant decrease in EPA and DHA 
content when EE and TAG fish oils were incubated at temperatures of 5-60oC for up 
to 21 days, despite an increase in PV and p-AV. Although oils may appear to be of high 
quality with low oxidative values, they may still contain high molecular weight 
polymers. Burkow and Henderson [57] for example, found that the polymer content 
increased rapidly in air-oxidised fish oils and that oils with identical PV and TBARS-
values could contain different polymer content. The same authors also observed a 
correlation between polymer increase and a decrease in total fatty acids, which they 
suggested indicated that polymers may be the main oxidation product in autoxidised 
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marine oils. The thin-layer chromatography method used in the present study for 
separating lipid classes would have been inadequate for visualising polymers, due to 
insufficient staining caused by the lack of double bonds, instead requiring alternative 
techniques such as high performance gel permeation chromatography as used by 
Burkow and Henderson [57]. The additional monitoring for oligomers (cross-reacted 
oxidised lipids) in n-3 rich marine oils is encouraged by the industry for which the 
European and British pharmacopeial monographs specify limits of ≤1.5 and 3.0%, 
respectively [28,58]. Nevertheless, although all oils in the current study exhibited no 
major signs of oxidation through standard analytical techniques it is unclear whether 
any other signs of oxidation had occurred, which could contribute to fatty acid losses. 
The encapsulation of marine oils together with the addition of antioxidants such as 
tocopherols (vitamin E) are commonly employed to stabilize n-3 oils [26]. However, 
exposure to air such as during the preparation of oils prior to analysis renders these 
processes ineffective. Thus, Bannenberg et al [16] suggest that the PV/p-AV ratio 
should be below 1 as an indicator of good analytical techniques, which was evident in 
the current study with PV/p-AV ranging from 0.11-0.96 (Table 4), as a PV/p-AV ratio 
>1 may indicate that oxidation, specifically primary oxidation, has occurred shortly 
before analysis due to a prolonged period of air exposure. Irrespective, even under 
normal storage conditions oxidation will still slowly occur. Accordingly, as in the study 
of Halvorsen and Blomhoff [30], but in contrast to Albert et al. [9], a significant 
negative relationship was observed between number of days until expiry and PV (r = -
0.6264, P = 0.001) as well as for the PV/p-AV ratio (r = -0.5832, P = 0.004) (Figure 
3). The number of days before expiry varied greatly between products from 122 to 974 
days, indicating the long shelf life of encapsulated fish oil products. This extended shelf 
life also presents a significant challenge in addressing potential variations between 
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product batches, both with regards to oxidation and fatty acid contents, with products 
with identical batch numbers being found in multiple stores/retailers regardless of 
branded or own-brand labels. Consequently, this often restricts studies to single-point 
analyses on products being tested as in the case of the present study. Nevertheless, 
collectively these results showed that, although encapsulated fish oil products undergo 
some form of oxidation during storage, they have the capacity to remain within 
acceptable levels during the course of their shelf life.       
 
4. Conclusion 
In summary, the present study showed that encapsulated fish oil products obtainable 
in the UK are available in TAG, EE or TAG/EE forms, which predominantly determine 
the levels of n-3 LC-PUFA offered to the consumer. Moreover, although some products 
may fall slightly short of the EPA+DHA contents stated on product labels they are, on 
the whole, compliant with local regulatory guidelines regarding labelling. 
Nevertheless, it is important that studies verify the actual oil capsule content when 
determining EPA+DHA contents to ensure an accurate representation of levels 
available to consumers. Similarly, all products tested were below oxidation limits set 
out for fish oils by pharmacopeial standards, with only a few samples exceeding the 
stricter industry imposed limits for PV. Further monitoring studies of this nature are 
merited as an effective way of maintaining quality control and ensuring products 
adhere to codes of standards. 
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Table 1. Sample information, according to manufacturer’s label, and the actual measured oil capsule content and EPA+DHA content of the 1 
encapsulated fish oil products sampled in the study. 2 
Sample Brand Oil Source 
No. 
Capsules 
Oil Content 
(mg.capsule-1) 
EPA+DHA 
(mg.capsule-1) 
Expiry Date  
(days to expiry¶) 
Labelled Actual* Labelled Actual# 
Fish oils 
1 Own Brand Cod Liver 60 1000 1007 180 173 Aug 2019 (914) 
2 Own Brand Cod Liver  60 410 409 66 77 Aug 2019 (914) 
3 Own Brand Cod Liver / Fish  30 500 504 93 107 Sept 2019 (944) 
4 Own Brand Cod Liver / Fish (body) 60 500 494 93 105 Jun 2019 (852) 
5 Own Brand Cod Liver / Fish 60 500 510 93 109 Sep 2019 (944) 
6 Own Brand Cod Liver / Fish  90 1000 992 187 207 Apr 2019 (791) 
7 Own brand Cod Liver / Fish 30 250 229 46 50 Jul 2018 (518) 
8 Branded Fish / Cod Liver  60 540 540 124 120 May 2018 (457) 
9 Own Brand Cod Liver / Fish  30 1000 967 187 208 Sep 2019 (944) 
10 Own Brand Fish  30 300 294 75 69 Dec 2018 (671) 
11 Branded Fish / Evening Primrose  60 500 469 122 116 Jan 2019 (702) 
12 Own Brand Fish (body) 30 1000 996 250 245 Oct 2019 (974) 
13 Own Brand Fish 30 1000 1189 260 291 Oct 2018 (610) 
14 Own Brand Fish (body) 30 1000 1018 250 269 Sep 2019 (944) 
15 Branded Fish 180 300 301 73 81 Aug 2017 (184) 
16 Own Brand Fish  90 1000 977 300 267 Aug 2019 (914) 
Fish oils and concentrates 
17 Branded Fish Concentrate / Cod Liver / Fish  60 1050 1070 360 326 Jan 2018 (337) 
18 Branded Fish Concentrate / Cod Liver / Fish  30 1050 1053 360 328 June 2017 (122) 
19 Branded Fish Concentrate / Cod Liver / Fish  60 525 532 155 172 May 2018 (457) 
20 Branded Fish Concentrate/ Fish  60 600 597 260 247 Nov 2017 (275) 
Fish oil concentrates 
21 Own Brand Fish Concentrate 60 1500 1509 450 486 Oct 2018 (610) 
22 Branded Fish Concentrate (body)  100 556 562 305 279 Sep 2018 (579) 
23 Own Brand Fish Concentrate  60 1360 1376 950 905 Oct 2018 (610) 
*Based on the analysis of individual capsules (minimum 15 per sample product)       3 
#EPA+DHA content calculated using actual measured oil content (mg.capsule-1) from pooled capsule oil (minimum 5 capsules per sample product)  4 
¶
Based on date analysed to label expiry date       5 
  6 
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Table 2. Lipid class composition (% of total lipid), as determined by HPTLC, of encapsulated fish oil products sampled in the present study. 7 
 
 
Sample Product 
Fish oils Fish oil / concentrate Concentrates 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 
Lipid class (% total lipid)                     
  Wax/Steryl ester 1.1 1.7 1.5 1.0 1.4 1.6 2.6 0.3 1.5 1.7 3.0 2.0 1.1 2.0 1.9 2.5 1.9 1.6 0.8 1.7 - - - 
  Ethyl ester - - - - - - - - - - - - - - - - 57.0 54.7 55.3 69.2 97.4 94.6 98.0 
  Triacylglycerol 88.3 92.0 89.4 87.5 86.2 87.9 85.2 89.2 85.4 83.5 86.1 83.9 81.0 84.0 83.8 85.1 35.2 36.2 38.8 21.5 - - - 
  Free Fatty Acid 0.8 0.5 0.9 1.2 0.8 0.8 1.8 0.9 0.6 1.2 0.6 0.7 1.1 0.6 1.0 0.6 0.3 0.7 0.4 0.4 0.9 0.7 0.6 
  Cholesterol/Sterol 2.3 1.8 1.6 2.5 2.6 2.4 1.7 2.8 5.2 2.4 1.8 3.4 3.4 3.4 2.9 2.4 1.3 1.7 1.2 1.6 1.0 1.4 0.4 
  Diacylglycerol 5.6 2.7 5.3 6.3 7.2 5.7 5.9 5.4 6.9 7.3 7.4 8.1 9.4 7.9 8.4 7.6 2.7 3.9 1.5 4.1 - - - 
Total neutral 98.1 98.7 98.7 98.5 98.2 98.4 97.2 98.6 99.6 96.1 98.9 98.1 96.0 97.9 98.0 98.2 98.4 98.8 98.1 98.5 99.3 96.7 99.0 
Pigmented/polar 
material 
1.9 1.3 1.3 1.5 1.8 1.6 2.8 1.4 0.4 3.9 1.1 1.9 4.0 2.1 2.0 1.8 1.6 1.2 2.0 1.5 0.7 3.3 1.0 
- not detected  8 
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Table 3. Fatty acid composition (% of total fatty acids) of oil from encapsulated fish oil products sampled in the study. 9 
 
 
Sample Product 
Fish Oils Fish oil / Concentrates Concentrates 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 
Fatty acid (% total lipid)                      
14:0 3.6 3.6 5.1 5.2 4.9 7.6 5.4 4.9 5.3 7.2 3.6 5.8 6.8 6.4 7.0 7.2 2.2 2.3 2.2 2.2 0.4 0.2 0.1 
16:0 9.8 9.9 13.3 13.3 13.2 18.8 13.7 12.9 12.4 17.8 11.6 15.1 16.1 16.1 16.7 16.1 7.4 8.8 7.8 7.6 7.6 0.6 0.2 
18:0 2.1 2.1 2.7 2.8 2.7 3.8 2.8 2.7 2.4 3.7 3.2 3.1 3.3 3.3 3.4 3.3 2.8 2.9 2.7 3.6 5.4 4.5 0.5 
20:0 0.1 0.0 0.3 0.3 0.3 0.6 0.2 0.3 0.3 0.5 0.3 0.5 0.5 0.5 0.3 0.2 0.5 0.5 0.5 0.8 0.4 1.0 0.3 
Total saturated1 15.9 16.0 21.9 22.2 21.5 31.7 23.1 21.6 21.1 30.1 19.3 28.4 27.8 27.0 28.4 27.4 15.1 14.9 13.4 15.0 14.0 7.0 1.5 
16:1n-7 7.6 9.0 8.6 8.5 8.4 10.4 8.6 8.6 9.0 9.7 6.4 8.4 9.2 8.7 8.7 8.7 4.7 4.9 4.6 3.7 2.5 0.5 0.1 
18:1n-9 17.8 17.1 13.7 13.3 14.2 11.3 12.8 13.2 12.7 10.9 7.1 9.3 10.2 8.8 8.6 8.0 11.9 11.8 11.6 7.3 17.5 8.3 2.0 
18:1n-7 4.4 4.9 3.9 3.9 3.8 3.5 3.8 4.0 3.7 3.4 2.9 2.9 3.0 3.1 3.2 3.1 3.5 3.6 3.4 3.0 5.2 3.3 0.9 
20:1n-11 1.8 1.1 1.0 0.9 0.9 0.2 1.6 0.6 0.9 0.2 0.2 0.2 0.2 0.2 0.2 0.2 1.2 1.0 1.0 0.3 0.4 0.3 0.1 
20:1n-9 12.0 11.9 6.7 6.9 6.8 1.9 5.4 7.1 6.0 1.8 1.5 1.7 1.6 1.8 1.4 1.1 6.9 6.4 7.1 2.6 2.0 3.0 1.0 
22:1n-11 8.9 6.5 5.1 5.2 5.1 1.6 4.1 3.7 4.3 1.5 1.3 1.8 1.3 1.8 1.1 0.8 6.1 6.5 5.9 2.3 1.3 2.0 0.4 
22:1n-9 0.9 0.7 0.6 0.6 0.6 0.3 0.5 0.5 0.5 0.3 0.2 0.3 0.3 0.3 0.3 0.2 0.8 0.8 0.8 0.6 0.2 0.6 0.1 
Total monoenes2 55.0 52.7 41.0 40.6 41.2 30.7 38.2 39.0 38.4 29.1 20.6 25.7 27.0 26.0 24.7 23.5 36.7 36.6 35.8 21.4 29.9 19.3 4.8 
18:2n-6 1.6 2.1 1.6 1.5 1.5 1.5 1.8 2.1 1.6 1.4 17.0 1.6 1.4 1.3 1.2 1.3 1.4 1.2 1.3 1.0 4.1 1.2 0.6 
18:3n-6 0.1 0.2 0.2 0.2 0.2 0.3 0.2 0.2 0.2 0.3 2.4 0.3 0.3 0.3 0.3 0.3 0.1 0.2 0.2 0.2 0.3 0.2 0.1 
20:2n-6 0.3 0.3 0.2 0.2 0.2 0.2 0.2 0.3 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.3 0.3 0.3 0.3 0.3 0.3 0.3 
20:4n-6 0.4 0.4 0.8 0.8 0.8 1.5 0.8 0.8 0.9 1.4 1.3 1.1 1.3 1.2 1.3 1.1 1.3 1.4 1.3 2.1 2.0 2.0 5.0 
Total n-6 PUFA3 2.5 3.1 3.1 3.1 3.1 4.2 3.4 3.7 3.3 4.0 21.4 3.9 3.7 3.5 3.5 3.5 3.9 3.6 3.7 4.6 7.4 4.8 8.1 
18:3n-3 0.8 0.9 0.8 0.8 0.8 0.9 0.9 0.9 0.9 0.8 0.7 0.8 0.8 0.8 0.7 0.9 0.7 0.7 1.0 0.6 1.7 0.9 0.3 
18:4n-3 2.6 2.6 2.8 2.9 2.8 1.8 2.8 3.0 3.0 2.2 2.7 3.4 2.9 3.4 2.7 3.1 2.2 2.1 2.5 1.8 4.1 3.1 1.0 
20:4n-3 0.8 0.7 0.9 0.9 0.9 1.0 0.7 0.8 1.0 0.9 1.0 1.0 0.8 1.0 0.8 0.8 1.1 1.0 1.2 1.3 1.2 1.9 2.0 
20:5n-3 (EPA) 8.6 8.8 13.5 13.5 13.6 14.6 13.9 13.8 15.0 16.5 22.1 17.9 18.1 18.7 19.2 19.5 19.9 20.3 20.6 28.9 25.8 33.8 53.0 
22:5n-3 (DPA) 1.2 1.2 1.5 1.5 1.6 1.8 1.4 1.5 1.7 1.9 1.3 1.8 1.9 1.9 2.1 2.2 2.7 2.6 2.7 3.9 1.7 3.5 4.7 
22:6n-3 (DHA) 11.2 12.9 11.1 11.2 11.2 10.2 11.8 12.4 12.4 11.3 6.5 12.0 11.8 12.5 12.5 12.5 15.8 16.0 16.8 19.7 12.2 23.8 22.2 
Total n-3 PUFA4 25.7 27.4 31.3 31.5 31.6 31.0 32.1 33.1 34.7 34.3 35.1 37.7 36.9 39.0 38.7 39.9 43.5 43.9 46.0 57.8 47.5 68.7 85.6 
Total PUFA5  29.1 31.3 37.1 37.2 37.2 37.6 38.7 39.4 40.5 40.8 60.1 45.9 45.2 47.1 46.9 49.1 48.2 48.5 50.8 63.6 56.1 73.7 93.7 
EPA+DHA 19.8 21.7 24.6 24.7 24.8 24.8 25.7 26.2 27.4 27.8 28.6 29.9 29.9 31.2 31.7 32.0 35.7 36.3 37.4 48.6 38.0 57.6 75.2 
EPA+DPA+DHA 21.0 22.9 26.1 26.2 26.4 26.6 27.1 27.7 29.1 29.7 29.9 31.7 31.8 33.1 33.8 34.2 38.4 38.9 40.1 52.5 39.7 61.1 79.9 
1includes 15:0, 22:0 and 24:0 10 
2includes 16:1n-9, 17:1, 20:1n-7 and 24:1n-9 11 
3includes 20:3n-6, 22:4n-6 and 22:5n-6 12 
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4includes 20:3n-3 and 21:5n-3 13 
5includes 16:2, 16:3 and 16:4 14 
  15 
www.ejlst.com                                                                 European Journal of Lipid Science and Technology 
 
 
 
  
 
cc
ep
te
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
d
A
  A
rt
ic
le
32 
 
Table 4. Primary (PV, meq.kg-1) and secondary oxidation markers (p-AV; TBARS, mg MDA.kg-1; FFA, %), total oxidation (TOTOX; 2PV 16 
+AV) and ratio of PV/AV of encapsulated fish oil products sampled in the study. 17 
 Sample Product 
 Fish oils Fish oils / Concentrates Concentrates 
 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 
PV (meq.kg-1) 2.46 3.57 2.60 3.88 2.67 2.59 3.70 3.97 1.44 4.43 4.37 1.74 2.86 2.20 3.96 2.08 4.52 4.26 5.20 6.76 4.15 6.84 7.04 
AV 9.83 6.11 12.70 9.58 11.90 9.88 10.59 7.26 13.63 13.56 9.24 8.63 15.63 12.20 11.37 14.34 6.43 8.64 10.41 7.03 11.54 7.59 9.54 
TOTOX 14.75 13.25 17.90 17.34 17.24 15.06 17.99 15.20 16.51 22.42 17.98 12.11 21.35 16.60 19.29 18.50 15.47 17.16 19.84 20.81 20.55 21.27 23.62 
PV/AV 0.25 0.58 0.20 0.41 0.22 0.26 0.35 0.55 0.11 0.33 0.47 0.20 0.18 0.18 0.35 0.15 0.70 0.49 0.50 0.96 0.36 0.90 0.74 
                        
TBARS 
(mg MDA.kg-1) 
0.27 0.19 0.19 0.46 0.17 0.56 0.26 0.16 0.27 1.37 0.11 0.29 1.39 0.15 0.31 0.41 0.99 0.33 2.49 0.51 0.52 0.56 1.32 
FFA (%) 0.33 0.31 0.57 0.35 0.39 0.42 1.19 0.36 0.38 0.66 0.42 0.38 0.52 0.38 0.60 0.38 0.38 0.40 0.54 0.35 0.40 0.36 0.45 
Limit of PV, AV and TOTOX for marine oils of 10 meq.kg-1 30 and 50, respectively, by the British and European pharmacopeias or 5 meq.kg-1 20 and 26, respectively, by GOED [25,26].  18 
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Figure Legends 
Figure 1. The actual capsule oil content measured of fish oil products relative to the 
claimed content (dotted line).  
Figure 2. The EPA+DHA content of encapsulated fish oil products relative to the 
labelled content (dotted line) based on claimed and actual capsule oil contents. 
Figure 3. The relationship between days to expiry and (a.) PV and (b.) PV/p-AV ratio 
of encapsulated fish oil products analysed in the present study.   
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Figure 3. 
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